selegiline / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   6 Trials   6 Trials   451 News 


«12345»
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Review, Journal:  Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations. (Pubmed Central) -  May 22, 2023   
    Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson's disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.
  • ||||||||||  selegiline / Generic mfg.
    Journal:  Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism. (Pubmed Central) -  May 17, 2023   
    Eleutheroside E can improve the MPTP-induced apoptosis of PC-12 cells by increasing the mitochondrial membrane potential and reducing the level of intracellular reactive oxygen species (ROS). Moreover, the apoptosis of cells is regulated by the expression of CytC, Nrf2, and NQO1 proteins.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Review, Journal:  A comprehensive review of the docking studies of chalcone for the development of selective MAO-B inhibitors. (Pubmed Central) -  May 16, 2023   
    Here we focused on the interactions between reported chalcone derivatives and the active site of monoamine oxidase B and the influence of substitutions on those interactions. Detailed images illustrating the interactions and impact of the substituents or structural modifications on these interactions were used to support the docking results.
  • ||||||||||  selegiline / Generic mfg.
    Preclinical, Journal:  Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice. (Pubmed Central) -  Apr 4, 2023   
    in HFD-fed mouse livers and PA-treated AML-12 cells. In conclusion, our findings suggest that selegiline exerts protective effects against HFD-induced dyslipidemia and hepatic steatosis, which may be related to an improved inflammatory response, oxidative stress, and hepatic lipid metabolism.
  • ||||||||||  Review, Journal:  Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology. (Pubmed Central) -  Dec 24, 2022   
    We will be focusing on banisterine, iproniazid, selegiline, rasagiline, tranylcypromine, moclobemide, and their role in the history of psychopharmacology. An almost unknown fact is that harmine, an MAO-A alkaloid, was used as early as the latter half of the 1920s in Bucharest, to reduce catatonic symptoms in schizophrenia, thus ushering the dawn of psychopharmacology era which started with chlorpromazine in the 1950s.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Biomarker, Journal:  Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On. (Pubmed Central) -  Nov 26, 2022   
    Although preliminary and limited, this study indicates that patients under different iMAO-Bs may present distinct profiles of CSF neurodegeneration-related biomarkers, probably because of the differential neurobiological effects of the drugs. Larger studies are now needed to confirm and extend these initial observations.
  • ||||||||||  selegiline / Generic mfg.
    P1 data, Journal:  First-in-human evaluation of F-SMBT-1, a novel F-labeled MAO-B PET tracer for imaging reactive astrogliosis. (Pubmed Central) -  Oct 6, 2022   
    To ascertain F-SMBT-1 selectivity to MAO-B, 9 participants underwent 2 F-SMBT-1 scans, before and after receiving 5 mg of selegiline twice daily for 5 d. To compare selectivity, F-THK5351 studies were also conducted before and after selegiline...Moreover, F-SMBT-1 brain distribution matches the reported in vitro distribution and captures the known MAO-B increases with age, suggesting F-SMBT-1 can potentially be used as a surrogate marker of reactive astrogliosis. Further validation of these findings with F-SMBT-1 will require examination of a much larger series, including participants with MCI and AD.
  • ||||||||||  selegiline / Generic mfg.
    Improvement of movement disorder and neurodevelopment under selegiline in a CLTC deficient patient (Poster Station: 13) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_222;    
    Defective CLTC protein may result in imbalance of biogenic amines in the synaptic cleft by altering their synaptic turnover. The striking improvement of the movement disorder and the neurodevelopment under the irreversible MAO-B inhibitor and functional studies support this hypothesis.
  • ||||||||||  selegiline / Generic mfg., rasagiline / Generic mfg.
    Review, Journal:  Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies. (Pubmed Central) -  Aug 30, 2022   
    Clinically approved MAO inhibitors for example selegiline, rasagiline, clorgyline, pargyline etc. are irreversible in nature and cause some adverse effects while recently studied reversible MAO inhibitors are devoid of harmful effects of old monoamine oxidase inhibitors. In this review article we have listed various synthesized molecules containing different moieties like coumarin, chalcone, thiazole, thiourea, caffeine, pyrazole, chromone etc. along with their activity, mode of action, structure activity relationship and molecular docking studies.
  • ||||||||||  selegiline / Generic mfg.
    Preclinical, Journal:  Chronic treatment with enhancer drugs modifies the gene expression of selected parameters related to brain plasticity in rats under stress conditions. (Pubmed Central) -  Aug 24, 2022   
    Selegiline, also known as L-deprenyl, and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) were found to induce enhancement of monoamine neurotransmission in low and very low doses...Observed changes may indicate a positive influence of enhancer drugs on brain plasticity, which is important for preventing negative consequences of chronic stress and enhancement of stress resilience. It may be suggested that the changes in glutamate receptor subunits induced by enhancer drugs are brain region-specific and not dose-related.
  • ||||||||||  selegiline / Generic mfg.
    Journal:  Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage. (Pubmed Central) -  Aug 22, 2022   
    Nigral iron is lower before the start of dopaminergic medication and then increases throughout the disease until it plateaus at late stages, suggesting increased iron may not be an etiological factor. Interestingly, PD medications may have differential associations with iron accumulation that need further investigation.
  • ||||||||||  selegiline / Generic mfg.
    Journal:  Antibody-Mediated Screening of Peptide Inhibitors for Monoamine Oxidase-B (MAO-B) from an Autodisplayed F Library. (Pubmed Central) -  Jun 22, 2022   
    The gene expression pattern in astrocytes after treatment with the two mimotopes was also analyzed and compared with that in the human astrocytes treated with selegiline. Finally, the interaction between two mimotopes and MAO-B was analyzed using docking simulation, and the candidate regions of MAO-B for the interaction with each mimotope were explored through the docking simulation.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Review, Journal:  A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. (Pubmed Central) -  Jun 15, 2022   
    Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson's disease, an option which is too often not appreciated properly.
  • ||||||||||  betahistine / Generic mfg., selegiline / Generic mfg.
    Journal, Combination therapy:  Low Dose Betahistine in Combination With Selegiline Increases Cochlear Blood Flow in Guinea Pigs. (Pubmed Central) -  Jun 8, 2022   
    This should be investigated in further studies regarding dose-effect relation in comparison to betahistine alone. Side effects, in particular regarding circulation, should be considered carefully in view of the clinical applicability of a combination therapy in patients with MD.
  • ||||||||||  pramipexole IR / Generic mfg., selegiline / Generic mfg.
    Preclinical, Journal:  Intrathecal pramipexole and selegiline for sensory and motor block in rats. (Pubmed Central) -  May 29, 2022   
    The duration of the spinal anesthetic effect of pramipexole was longer than lidocaine. At a non-effective dose, pramipexole increased the duration of efficacy of lidocaine.
  • ||||||||||  selegiline / Generic mfg., rasagiline / Generic mfg.
    Journal:  The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. (Pubmed Central) -  May 12, 2022   
    Interestingly, dialysis studies found that 2-PAT is a reversible MAO-A inhibitor, while acting as an inactivator of MAO-B. Since reversible MAO-A inhibitors are much less liable to potentiate tyramine-induced side effects than MAO-A inactivators, it is reasonable to suggest that 2-PAT could be a useful and safe therapeutic agent for disorders such as Parkinson's disease and depression.
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal
    Reimbursement, Journal, Medicare:  Difference in rural and urban Medicare prescription pattern for Parkinson's disease in Hawai'i. (Pubmed Central) -  May 7, 2022   
    In the state of Hawai'i, there is an urban-rural access gap to neurologists as evidenced by Medicare prescription pattern. Further study is needed to understand the reasons for rural-urban differences in prescription patterns and their impact on outcomes.
  • ||||||||||  Review, Journal:  Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. (Pubmed Central) -  May 6, 2022   
    Finally, the non-medical use of any potent psychotropic raises serious ethical and legal issues, with nootropics having the potential to become a major public health concern. Further studies investigating CE-associated social, psychological, and biological outcomes are urgently needed to allow firm conclusions to be drawn on the appropriateness of CE use in healthy individuals.
  • ||||||||||  selegiline / Generic mfg.
    Journal:  Mitigated Oxidative Stress and Cognitive Impairments in Transient Global Ischemia using Niosomal Selegiline-NBP delivery. (Pubmed Central) -  May 3, 2022   
    These data manifested that the selegiline-NBP nanoformulation (0.5-1 mg/kg) could significantly reduce oxidative damage, cognitive dysfunction, and histopathological damage compared to transient hypoxia-ischemia rats, which is 20 times lower than the therapeutic dose in humans. Therefore, the proposed nanoformulation would be capable as an alternative candidate without side effects in stroke.
  • ||||||||||  rasagiline / Generic mfg.
    Journal:  Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. (Pubmed Central) -  Apr 5, 2022   
    MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce "OFF" time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.